Ann: Paradigm doses first participant in Synovial Fluid Trial, page-10

Less underappreciating, more simply no knowledge of what 008 is, what it's aim is, what it means, the ramifications. To most, 008 just represents another study...


The average person (even some shareholders) have little idea what biomarkers are, and why they make a difference and what our drug does with them.......this will, in my views only, be spelt out when the data flows as we progress through 008....the market response will most likely be lagged and will realise this after it is explained, maybe even days after the results are announced.

Not being cynical or negative...just how it is...our brighter times are on the way...


DYOR, my views expressed here.